Falling asleep to your favorite show doesn't have to ruin your sleep, experts say
While you don't want to expose yourself to the light from screens before sleep, listening to a show or podcast can be done without ruining your night, experts say. whitebalance.space/E+/Getty Images via CNN Newsource
You've heard the rule: No TV before bed.
But many people find that it helps them fall asleep if they listen to something –– audiobooks, music, podcasts or TV shows.
A 2018 study found that more than half of people with sleep disturbances use music as a sleep aid.
It is poor sleep hygiene to look at screens to scroll or watch a show before bedtime, but what if you aren't looking, just listening?
'It's like Goldilocks,' said sleep medicine specialist Dr. Rachel Salas, professor of neurology at the Johns Hopkins University School of Medicine in Baltimore. 'It's a matter of what works for you … It's not only the practices of your bedtime routine, but your environment, all the things.'
Everyone is different, and some people might get great sleep if they fall asleep listening to something, Salas said. However, there are some practices to keep in mind to make sure you are maximizing the benefits and avoiding potential pitfalls.
Winding down to sleep
The key to listening to audiobooks, podcasts, music or TV to fall asleep is making sure it is helping you wind down instead of waking you up, said Dr. Shalini Paruthi, sleep medicine attending physician at John J. Cochran Veterans Hospital in St. Louis and adjunct professor at St. Louis University School of Medicine.
'If listening to something actually keeps a person more engaged or awake and therefore replaces sleep time, this can be detrimental to health,' she said in an email. 'It is recommended that adults obtain at least 7 hours of sleep regularly for optimal performance.'
On the other hand, a predictable kind of noise can help tell your body it's time to wind down, Salas added.
'If you find that that's part of your bedtime routine, and it's kind of comforting and relaxing … that's great,' she said.
Try choosing content to listen to that will allow you to transition into sleep, added Dr. Lindsay Browning, a psychologist and sleep expert in Berkshire in the United Kingdom.
'Choose something not too engaging so that your brain isn't motivated to stay awake and fight sleep to pay attention to it,' she said in an email.
A sleep story may be a better choice than audio of a book you want to read. Shows you have heard before and know how they end might be better than falling asleep to a nailbiter.
When to turn the sound off
A soundtrack for sleep might help you get to sleep, but it doesn't always keep you asleep if it keeps going all night, Browning said.
'It's important to set an auto timer to mute the sounds as soon after falling asleep as possible,' she said.
If the show, podcast, or music you are playing has unexpected noises, frequencies or volumes, it might alert your brain to pay attention, Salas said. The startling noise doesn't always wake you up fully, but it can cause many little awakenings you aren't aware of. That will disturb your sleep nonetheless, she added.
One steady sound, like white noise or ASMR, can help your sleep quality, especially if you live in a noisy area, Salas added.
'(If) bars close at a certain time and people are outside, walking home and talking or yelling, that's going to disrupt your sleep,' she said.
A consistent and non-alarming noise can stifle those kinds of ambient noise, she said.
What to do about insomnia
Sometimes listening to something to fall asleep isn't just a nice part of a bedtime routine –– it's a way to quiet racing thoughts at night. Some proactive steps during the day may help, Browning said.
'If you find that your brain is too active as you try to fall asleep, which keeps you awake, you could try to address those busy thoughts and worries earlier in the day,' she said.
Methods include having a dedicated time earlier in the day to think about those worries or utilizing cognitive shuffling, a technique that involves thinking up random and non-emotionally charged words to take your mind off of your racing thoughts, Browning said.
'It's a much better idea to try to learn ways of quieting a busy mind at night that don't require you to mask those unwanted thoughts with an external sound,' Browning said.
If you are using listening to something to help with insomnia and it doesn't seem to help after a two-to-four-week period, it might be time to see a board-certified sleep physician and get to the root of the problem, Paruthi said.
'There are several proven therapies that work well for insomnia treatment such as cognitive behavior therapy for insomnia, or when appropriate, medications can be considered,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a day ago
- Globe and Mail
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
Viking Therapeutics (VKTX) is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of over 200%, the stock has captured the attention of growth-focused investors. Backed by a strong pipeline targeting obesity and liver diseases, Viking's innovative therapies could pave the way for major breakthroughs and significant shareholder returns. Confident Investing Starts Here: VKTX's Bullish Case Viking Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies targeting metabolic and endocrine disorders. Their pipeline includes promising candidates for treating obesity, non-alcoholic fatty liver disease (NAFLD), and muscle wasting. Understandably, clinical-stage biotech firms come with high risk. Their treatments might never make it through trials or reach the market, and even if they do, profits aren't guaranteed. The company currently has no approved products, no revenue, and runs at a loss. During times of market uncertainty, investors often shy away from companies like this. However, Viking Therapeutics stands out from many other biotech firms. It's working on treatments for several major health issues, especially in areas where better options are needed. One key focus is weight loss, a market that's been growing fast and still has a lot of room to expand. Viking's top drug candidate, VK2735, targets both GLP-1 and GIP receptors, a combination found in Eli Lilly's (LLY) Zepbound, the current market leader and only approved drug of its kind so far. Additionally, the company is seeing encouraging results from its mid-stage program VK2809, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). For context, MASH is a liver disease linked to obesity and becoming increasingly common. While the FDA only approved the first treatment for MASH last year, more approvals are expected shortly. Is Viking Therapeutics a Good Stock to Buy? Viking Therapeutics stock carries high risk, making it unsuitable for cautious investors. However, for those comfortable with volatility, a small position could offer strong long-term upside while limiting potential losses if the company fails. According to TipRanks, VKTX stock has received a Strong Buy consensus rating, with 13 Buys and one Hold assigned in the last three months. The average Viking Therapeutics stock price target is $90.7, suggesting a potential upside of nearly 217.32% from the current level. Year-to-date, VKTX stock has declined by almost 30%. See more VKTX analyst ratings


Globe and Mail
a day ago
- Globe and Mail
From Scrubs to Coats: Zenir Introduces New White Lab Coat Collection for Healthcare Professionals
Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Torrance, California--(Newsfile Corp. - June 14, 2025) - Zenir, the trusted name in premium medical scrubs, has officially expanded its product lineup with the launch of its first white lab coats available now for both men and women in short and long lengths. Known for combining functional innovation with elevated style, Zenir continues to raise the standard for medical workwear with this new release. To view an enhanced version of this graphic, please visit: The newly launched white lab coats faithfully embody Zenir's philosophy of comfort, practicality, and refined style. The short-length lab coat is engineered with a three-dimensional pattern that naturally facilitates shoulder and arm movement ideal for dynamic, active roles while the long lab coat features a subtly cinched waistline and matte hidden snap buttons to deliver a sleek, professional silhouette in clinical settings. Meticulously designed storage details, such as a dedicated pen holder in the chest pocket and an inner pocket for smartphones, balance functionality with clean design. Optimized for fast-paced healthcare environments, this collection not only meets workplace requirements but also offers a range of fits and style options to suit every body shape and individual preference. Already recognized for its high-performance scrubs, Zenir is a brand trusted by thousands in the healthcare industry and has sold more than 3 million units globally. The brand has earned its reputation for premium-quality scrubs that are breathable, durable, wrinkle-resistant, and moisture-wicking, now extended to its latest line of white lab coats. As Zenir continues to grow its presence beyond Korea, this expansion into white lab coats marks a milestone in Zenir's commitment to offering a complete spectrum of medical workwear solutions. With thoughtfully tailored cuts, sustainable production using GRS-certified recycled fibers, and a design-first approach, Zenir's new white lab coats are built for professionals who expect more from their daily uniform. For more details, visit


Globe and Mail
a day ago
- Globe and Mail
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow stocks in May -- both from the healthcare sector -- kept the index's rally in check, with one of them plunging over 25%. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » 1. UnitedHealth Group Shares of UnitedHealth Group (NYSE: UNH) crashed 26.6% in May after multiple negative developments sent shockwaves through the investing community. In mid-May, UnitedHealth suddenly replaced its CEO, Andrew Witty, with former CEO Stephen J. Hemsley with immediate effect and suspended its earnings outlook for the full year because of a surge in medical costs. In between, The Wall Street Journal reported a criminal investigation against UnitedHealth by the Department of Justice for a "possible medicare fraud." Days later, The Guardian released a scathing report alleging UnitedHealth put patients' health at risk by paying secret bonuses to nursing homes to cut hospital transfers. For now, UnitedHealth expects to "return to growth" in 2026 and has sued The Guardian for defamation. Regaining investor confidence, however, may not be easy. The stock is down 38% so far this year, as of this writing. 2. Merck Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices of prescription drugs. This comes at a time when Merck already expects tariffs to add $200 million to its costs this year. Investors are also worried about Merck's future once its blockbuster oncology drug Keytruda loses patent exclusivity. In mid-May, analysts at Citi slashed Merck stock's price target to $84 per share from $115 per share citing the pharmaceutical company's growth challenges and a "lack of urgency" to develop a business that could soften the impact of a potential loss of up to 20% of sales for Keytruda once its patent expires. Merck, however, has a strong pipeline, remains committed to dividend growth, and yields 3.9%. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025